Paraproteinemic renal diseases that involve the tubulo-interstitium

Contributions to Nephrology

Volumn 153, Issue , 2007, Pages 105-115

  Herrera, Guillermo A ^a   Sanders, Paul W ^b,c,d,e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

BIOPSY; HUMAN; IMMUNOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; METABOLISM; PARAPROTEINEMIA; PATHOLOGY; REVIEW;

BIOPSY; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; NEPHRITIS, INTERSTITIAL; PARAPROTEINEMIAS;

EID: 33751511154     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000096763     Document Type: Review

References (51)

1. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH: Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991;64:527-537.
2. Berggård I, Peterson PA: Polymeric forms of free normal κ and λ chains of human immunoglobulin. J Biol Chem 1969;244:4299-4307.
3. Pesce AJ, Clyne DH, Pollak VE, Kant SK, Foulkes EC, Selenke WM: Renal tubular interactions of proteins. Clin Biochem 1980;13:209-215.
4. Bradwell AR, Mead GP, Carr-Smith HD: Diseases with increased polyclonal free light chains; in Serum Free Light Chain Analysis, ed 3. Birmingham, UK, The Binding Site Ltd., 2005, pp 175-194.
5. Batuman V, Dreisbach AW, Cyran J: Light-chain binding sites on renal brush-border membranes. Am J Physiol 1990;258(pt 2):F1259-F1265.
6. Batuman V, Guan S: Receptor mediated endocytosis of Bence-Jones proteins by proximal tubule cells. Am J Physiol 1997;272:F521-F530.
7. Batuman V, Verroust PJ, Navar GL, et al: Myeloma light chains are ligands for cubilin (gp280). Am J Physiol 1998;275(pt 2):F246-F254.
8. Klassen RB, Allen PL, Batuman V, Crenshaw K, Hammond TG: Light chains are a ligand for megalin. J Appl Physiol 2005;98:257-263.
9. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D: Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 1979;16:251-270.
10. Christensen EI, Devuyst O, Dom G, et al: Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci USA 2003;100:8472-8477.
11. Kozyraki R, Fyfe J, Verroust PJ, et al: Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia. Proc Natl Acad Sci USA 2001;98:12491-12496.
12. Day ED: The light chains of immunoglobulins; in Day ED (ed): Advanced Immunochemistry. New York, Wiley, 1990, pp 3-51.
13. Bruccoleri RE, Haber E, Novotny J: Structure of antibody hypervariable loops reproduced by a conformational search algorithm. Nature 1988;335:564-568.
14. Chothia C, Lesk AM: Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987;196:901-917.
15. Chothia C, Lesk AM, Tramontano A, et al: Conformations of immunoglobulin hypervariable regions. Nature 1989;342:877-883.
16. L domain of the antibody McPC603 produced in Escherichia coli. J Mol Biol 1990;213:613-615.
17. κI subgroup (ISE) in light chain deposition disease. Clin Exp Immunol 1993;91:506-509.
18. Solomon A: Light chains of immunoglobulins: structural-genetic correlates. Blood 1986;68:603-610.
19. Mian IS, Bradwell AR, Olson AJ: Structure, function and properties of antibody binding sites. J Mol Biol 1991;217:133-151.
20. Birn H, Spiegelstein O, Christensen EI, Finnell RH: Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol 2005;16:608-615.
21. Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V: Endocytosis of light chains induces cytokines through activation of NF-κB in human proximal tubule cells. Kidney Int 2002;62:1977-1988.
22. Sengul S, Zwizinski C, Batuman V: Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 2003;284:F1245-1254.
23. Arimura A, Li M, Batuman V: Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 2006;107:661-668.
24. Birn H, Christensen EI: Renal albumin absorption in physiology and pathology. Kidney Int 2006;69:440-449.
25. Katzmann JA, Clark RJ, Abraham RS, et al: Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-1444.
26. Sanders PW, Herrera GA, Galla JH: Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int 1987;32:851-861.
27. Sanders PW, Herrera GA, Chen A, Booker BB, Galla JH: Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest 1988;82:2086-2096.
28. Sanders PW, Booker BB, Bishop JB, Cheung HC: Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 1990;85:570-576.
29. Deret S, Denoroy L, Lamarine M, et al: Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng 1999;12:363-369.
30. Decourt C, Bridoux F, Touchard G, Cogne M: A monoclonal V κl light chain responsible for incomplete proximal tubulopathy. Am J Kidney Dis 2003;41:497-504.
31. Sanders PW, Booker BB: Altered loop segment function is the initial event in precipitation of low molecular weight proteins in the rat nephron; in Bianchi C, Carone FA, Rabkin R (eds): Contributions to Nephrology. Switzerland, S. Karger AG, 1991, pp 100-103.
32. Sanders PW, Booker BB: Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992;89:630-639.
33. Huang Z-Q, Kirk KA, Connelly KG, Sanders PW: Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Invest 1993;92:2975-2983.
34. Huang Z-Q, Sanders PW: Biochemical interaction of Tamm-Horsfall glycoprotein with Ig light chains. Lab Invest 1995;73:810-817.
35. Huang Z-Q, Sanders PW: Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 1997;99:732-736.
36. Hoyer JR, Seiler MW: Pathophysiology of Tamm-Horsfall protein. Kidney Int 1979;16:279-289.
37. Kumar S, Muchmore A: Tamm-Horsfall protein - uromodulin (1950-1990). Kidney Int 1990;37:1395-1401.
38. Rindler MJ, Naik SS, Li N, Hoops TC, Peraldi M-N: Uromodulin (Tamm-Horsfall glycoprotein/uromucoid) is a phosphatidylinositol-linked membrane protein. J Biol Chem 1990;265:20784-20789.
39. Ying W-Z, Sanders PW: Expression of Tamm-Horsfall glycoprotein is regulated by dietary salt in rats. Kidney Int 1998;54:1150-1156.
40. Weiss JH, Williams RH, Galla JH, et al: Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat. Kidney Int 1981;20:198-210.
41. Tanner GA, Knopp LC: Glomerular blood flow after single nephron obstruction in the rat kidney. Am J Physiol 1986;250(pt 2):F77-F85.
42. Tanner GA, Evan AP: Glomerular and proximal tubular morphology after single nephron obstruction. Kidney Int 1989;36:1050-1060.
43. Fields S, Song O: A novel genetic system to detect protein-protein interactions. Nature 1989;340:245-246.
44. Ying W-Z, Sanders PW: Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001;158:1859-1866.
45. Lenhoff S, Hjorth M, Holmberg E, et al: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
46. Fermand J-P, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-3136.
47. Badros A, Barlogie B, Siegel E, et al: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822-829.
48. Barlogie B, Shaughnessy J, Tricot G, et al: Treatment of multiple myeloma. Blood 2004;103:20-32.
49. Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N, Mahendra P: Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 2002;30:471-473.
50. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988;33:1175-1180.
51. Clark WF, Stewart AK, Rock GA, et al: Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial: Ann Intern Med 2005;143:777-784.